90 likes | 251 Views
Membranes Used in Drug Delivery. Walter Trachim BMCB658 3/2/12. Introduction. Membrane-based drug delivery systems have been developed for a number of reasons Size Timing Bioavailability Different types of delivery systems exist and are used in different applications.
E N D
Membranes Used in Drug Delivery Walter Trachim BMCB658 3/2/12
Introduction • Membrane-based drug delivery systems have been developed for a number of reasons • Size • Timing • Bioavailability • Different types of delivery systems exist and are used in different applications
Membrane- Based Delivery • A number of different membrane-based delivery systems exist. They include: • Liposome • Liposome/Nanoparticle Hybrid • PLGA
Delivery Systems • Liposomes – Single or multiple lipid bi-layers arranged in concentric circles designed to contain an aqueous solution • Reliable : • Biocompatible • Biodegradable • Can be scaled, or their size can be modified • Considerably lower toxicity levels
Delivery Systems • PLGA – Polylactide-co-glycolide • Pros • Biocompatible • Versatile – will encapsulate a wide variety of medications • Able to “tune” how drug is released • Cons • Can be inefficient at low pH • Degraded easily in acid environments
Membrane-Based Delivery • Liposome-Nanoparticle Hybrids • Can be hydrophilic (encapsulated in the liposome) or hydrophobic (embedded in the lipid bilayer) • Used primarily for diagnostic testing – imaging is a common application (PET, MRI) • Also used for chemotherapy, mainly as a guard against cytotoxicity
Membrane-Based Delivery • Liposome – Quantum Dot Hybrids • Semiconductors – have fluorescent qualities • Used for optically-based diagnostic applications • Also used for chemotherapy – less prone to leakage • LD50 found to be favorable for pulmonary imaging
Applications • Cancer treatment – chemotherapy • Pain management • Time-release • Anti-hypertensives • Anti-depressants • Sleep aids
References • Al-Jamal, W., & Kostarelos, K. (2011). Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine. Accounts of Chemical Research, 44(10), 1094-1104. doi:10.1021/ar200105p • Samstein, R., Perica, K., Balderrama, F., Look, M., Fahmy, T. (2007). The use of deoxycholic acid to enhance the oral bioavailability of biodegradable nanoparticles. Biomaterials, 29, 703-708. doi:10.1016/j.biomaterials.2007.10.026 • Wieber, A., Selzer, T., Kreuter, J. (2011). Characterisation and stability studies of a hydrophilic decapeptide in different adjuvant drug delivery systems: A comparative study of PLGA nanoparticles versus chitosan-dextran sulphate micriparticles versus DOTAP-liposomes. International Journal of Pharmaceutics, 421, 151-159. doi:/10.1016.j.ijpharm.2011.09.011